340 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
.
Operating Expenses
GAAP
% Change
Non-GAAP(a)
% Change
($ in millions)
Q1 2024
Q1 2023
Q1 2024
Q1 2023
Research and development (R&D)
Acquired … in-process research and development (IPR&D)
n/a
Selling, general, and administrative (SG&A)
Cost of goods sold (COGS)
Cost of collaboration and contract
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
% Change
Non-GAAP(a)
% Change
($ in millions)
Q4 2023
Q4 2022
Q4 2023
Q4 2022
Research and development (R&D)
Acquired in-process research and development … operating (income) expense, net
n/a
GAAP
% Change
Non-GAAP(a)
% Change
FY 2023
FY 2022
FY 2023
FY 2022
Research and development
Acquired in-process
8-K
EX-99.1
ekyrnvlarog0wak6p5oi
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
y9lz i2foivqxpm
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
qc04blph
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
8-K
6te6eqyu
5 Oct 23
Results of Operations and Financial Condition
4:04pm
SC TO-T/A
EX-99
liz5ss3
25 Sep 23
Third party tender offer statement (amended)
8:48am
SC TO-T
EX-99
6ohcp
25 Aug 23
Third party tender offer statement
7:46am
SC TO-C
EX-99.1
xi9 leqq2u
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
gqpb0np
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
EX-99.2
80vdg1g7
9 Aug 23
Information about tender offer
4:15pm
8-K
EX-99.1
nxef5djkqit9bbiotv7
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
tci48hd4 j8ph
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am